What the FDA labels say about taking them together
Atorvastatin and colchicine
Atorvastatin's FDA label of April 15, 2024 names colchicine in its drug interactions section, and colchicine's label names atorvastatin too. The atorvastatin label: “Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with LIPITOR.”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited).
What does the atorvastatin label say about colchicine?
Atorvastatin label, drug interactionsColchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with LIPITOR. Intervention: Consider the risk/benefit of concomitant use of colchicine with LIPITOR. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug.
Atorvastatin label, warnings and precautionsCases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ].
Source: FDA drug label (Atorvaliq, NDA213260), CMP Pharma, Inc., effective April 27, 2024 (SPL set 41fca2d8-7f3f-45b9-8974-81b89accc211), via openFDA
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the colchicine label say about atorvastatin?
Colchicine label, drug interactionsConcomitant Drug Class or Food: HMG-Co A Reductase Inhibitors: atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin; Noted or Anticipated Outcome: Pharmacokinetic and/or pharmacodynamic interaction: the addition of one drug to a stable long-term regimen of the other has resulted in myopathy and rhabdomyolysis (including a fatality); Clinical Comment: Weigh the potential benefits and risks and carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initial therapy; monitoring CPK (creatine phosphokinase) will not necessarily prevent the occurrence of severe myopathy.
Colchicine label, warnings and precautionsConcomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with colchicine may potentiate the development of myopathy [see Drug Interactions (7) ].
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Colchicine | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | Gout |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | $0.122 per tablet 0.6 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once